Enhancers provide critical information directing celltype-specific transcriptional programs, regulated by binding of signal-dependent transcription factors and their associated cofactors. Here, we report that the most strongly activated estrogen (E 2 )-responsive enhancers are characterized by trans-recruitment and in situ assembly of a large 1-2 MDa complex of diverse DNA-binding transcription factors by ERa at ERE-containing enhancers. We refer to enhancers recruiting these factors as mega transcription factorbound in trans (MegaTrans) enhancers. The MegaTrans complex is a signature of the most potent functional enhancers and is required for activation of enhancer RNA transcription and recruitment of coactivators, including p300 and Med1. The MegaTrans complex functions, in part, by recruiting specific enzymatic machinery, exemplified by DNA-dependent protein kinase. Thus, MegaTrans-containing enhancers represent a cohort of functional enhancers that mediate a broad and important transcriptional program and provide a molecular explanation for transcription factor clustering and hotspots noted in the genome.
INTRODUCTION
Functional specialization and precise patterning of different cell and tissue types are vital for all metazoans, which also generate cell-or tissue-specific gene expression patterns. Enhancers, initially defined as DNA elements that act over a distance to positively regulate expression of protein-encoding target genes, are the principle regulatory components of the genome that enable such cell-type-specific and signal-dependent patterns of gene expression (Banerji et al., 1981; Shlyueva et al., 2014) . Each cell type harbors more than 100,000 candidate enhancers in humans, vastly outnumbering protein-coding genes (Bernstein et al., 2012; Heintzman et al., 2009; Shlyueva et al., 2014) . This makes it very important to be able to predict and understand which enhancers are actually functionally required for target coding gene transcriptional regulation.
Enhancer activation requires the presence of specific recognition sequences for the cooperative recruitment of DNA-binding transcription factors (TFs) and their cofactors that initially activate gene expression (Rosenfeld et al., 2006) . While the role of a large number of coactivator complexes and their associated enzymatic activities is well established (Rosenfeld et al., 2006) , the precise biochemical mechanisms by which so many coactivators are recruited and required for the different functional activities at specific enhancer sites remain incompletely understood. Global genomic technologies have uncovered characteristic markers of enhancers and have provided clues as to their activation. Features that have been used to predict enhancers that are likely to be functional include the levels of enhancer RNAs (eRNAs) transcribed from enhancer-like regions in the genome , the presence of the histone acetyltransferase p300/CBP (Visel et al., 2009) , the timing of RNA Pol II occupancy (Bonn et al., 2012) , and levels of H3K4me2 and H3K27Ac (Chepelev et al., 2012; Heintzman et al., 2009 ). However, because enhancers identified using these features are not equally functional, additional methods are needed to distinguish the enhancers with different activation potential.
There are 2,600 DNA-binding TFs encoded by the human genome (Babu et al., 2004) , with 200-300 TFs being expressed in each cell type (Vaquerizas et al., 2009) . A long-standing question is how different TFs collaborate to regulate the enhancer network in a specific cell type. With the large expansion of genome-wide binding data, DNA-binding transcription factors were noted to co-bind to some so-called ''hotspot'' regions or to cooperatively cluster to some functional enhancers in various organisms or cell lines (Junion et al., 2012; Rada-Iglesias et al., 2012; Siersbaek et al., 2014a Siersbaek et al., , 2014b Wilson et al., 2010; Yan et al., 2013) . However, the underlying mechanism(s) and functional significance of this phenomenon are not well understood.
Recently, the idea of clustered enhancers associated with critical developmental or cancer-associated transcription units has been proposed Lové n et al., 2013; Whyte et al., 2013) . The initial definition of this super-enhancer model was described as clusters of enhancers spanning >8-10 kb, occupied by critical DNA-binding transcription factors at their cognate binding motifs (Lové n et al., 2013; Whyte et al., 2013) . These clustered super-enhancers control key coding transcription units in stem cells or various disease states and exhibit high levels of coactivators, which are suggested to contribute to gene activation. Cancer cells were also noted to acquire super-enhancers regulating oncogene drivers Lové n et al., 2013) . While the super-enhancer model can explain the higher expression levels for a small number of genes in some environments, it also highlights the need for exploring the functional activities of single enhancers in the regulation of coding genes critical for development and disease and understanding the phenomenon of TF clustering in short-range genomic regions.
Here, we report a signature of the functionally active estrogenregulated enhancers, particularly the 1,333 most active ERa enhancers linked to target coding gene activation. This signature is the selective recruitment in trans of an apparent complex of other DNA-binding TFs, including RARa/g, GATA3, AP2g, STAT1, AP1, and FoxA1. By gel filtration, we found these TFs migrated with ERa as a 1-2 MDa complex(es), referred to as the MegaTrans complex. The MegaTrans complex is almost invariably recruited to functional ERa-bound enhancers, 22% of which fit the criteria of being components of super-enhancers. Furthermore, the MegaTrans complex is required for activation of the functional enhancers, apparently based in part on specific recruitment of enzymes. This is exemplified by the functionally important recruitment of the DNA-dependent protein kinase to ERa-regulated enhancers by RARs. The MegaTrans complex, in turn, is also required for activation of eRNA transcription and recruitment of coactivators, including p300 and Med1, and thus exerts critical biological functions, conceptually parallel to what has been proposed for super-enhancers.
RESULTS

trans-Bound RARs on ERa Active Enhancers Regulate ERa Enhancer Function
ERa functions as a central transcription factor for gene programs that mediate cell growth and proliferation, and it accomplishes this role primarily through enhancer regulation. Among the total 7,174 ERa-bound enhancers, a subset of 1,333 enhancers that are located in proximity (<200 kb) to their regulated coding transcription units have proved to be the most significantly activated upon estrogen stimulation according to levels of H3K27Ac and increased eRNA transcription and appear to constitute the most potent functional enhancer program .
Our current study was initiated by investigating the possible functional mechanisms by which RARs on retinoic acid response element (RARE)-containing enhancers mediate RA-induced coding gene transcriptional programs, as well as the functional role(s) of RAR at enhancers that accommodate the effects of other signals, such as E 2 -induced coding gene transcriptional programs (Hua et al., 2009; Ross-Innes et al., 2010) . To distinguish the possible binding in cis (the chromatin association of a transcription factor through direct DNA binding at its recognition sites) and in trans (the chromatin association of a transcription factor through protein-protein interaction) functional models of RAR, we engineered MCF7 to express a bacterial biotin ligase (BirA) that can biotinylate a biotin ligase recognition peptide (BLRP)-tagged protein in vivo ( Figure S1A available online) . Under control of a Tet-On promoter, wild-type RAR and two DNA-binding domain mutants that cannot bind to RARE DNA sites (Figures S1B and S1C) were expressed at similar levels as the endogenous proteins upon doxycycline induction ( Figure S1D ). Using these lines, we first performed biotin chromatin immunoprecipitation sequencing (ChIP-seq) for wild-type (WT) and mutant RARa/g (RARb is not expressed in MCF7 breast cancer cells) upon RA and E 2 stimulation. Comparing wild-type and non-DNA-binding mutants, we found that 15,000/18,000 of WT RARa/g-bound sites required the intact RAR DNA-binding ability because binding was lost with mutant RARs, and none of these sites were bound by ERa (Figures S1E-S1G). Among these 15,000 sites, 3,540 were enhancers that exhibited RA activation ( Figure S1E ), exemplified by the 700 most active RAR cis-binding enhancers, which showed significant RA-induced eRNA and gene target activation by global run-on sequencing (GRO-seq) ( Figure S1H ).
However, there were 3,000 RARa/g binding sites that did not depend on RAR DNA-binding ability ( Figures S1E and S2A) . Remarkably, we found that both RARa and RARg were recruited to virtually all of the ERa-bound 1,333 active enhancers in response to E 2 ( Figure 1A ). This observation is consistent with previous evidence that RAR can bind to ERa binding sites, although conflicting conclusions were reached regarding its activating or repressive effects (Hua et al., 2009; Ross-Innes et al., 2010) . However, ERa did not exhibit colocalization with RARs on ERa non-active enhancers ( Figure 1B) . By comparing the binding patterns of wild-type and two non-DNA-binding mutants, we found the binding of RARs on the 1,333 ERa active enhancers was in trans (Figures 1C and S2A) .
Knockdown of either RARa or RARg caused a significant decrease in both E 2 -dependent induction of eRNAs and activation of target coding genes, while knockdown of both caused almost complete inhibition, as assessed by quantitative PCR (qPCR) of targets such as GREB1 and TFF1 ( Figure 1D ). The knockdown of RARa and RARg, which was confirmed for both RNA and protein levels ( Figures S2B and S2C ), inhibited RA induction of the HoxA1 gene target as expected ( Figure 1E ). Boxplot analysis of the GRO-seq experiments showed that the presence of RARs was required for effective induction of both eRNAs and target coding gene transcription units upon E 2 treatment ( Figures 1F and S2D ). RARa/g knockdown also inhibited classical RAR cis-bound enhancers and their target genes ( Figures  S1H and S2E) . Thus, while RAR binding in cis activates a distinct RA-responsive transcriptional program, its recruitment in trans is also required for effective E 2 -dependent activation of ERabound functional enhancers.
Next, we utilized wild-type and pBox mutant RARg to test their ability to rescue ERa-regulated enhancer function following endogenous RARg knockdown ( Figure S2F ). Intriguingly, the non-DNA-binding mutant receptor continued to be effectively recruited to the ERa-bound regulatory enhancers at the GREB1 gene ( Figure S2A ) and was capable of restoring full E 2 -dependent GREB1 gene activation in rescue experiments ( Figure 1G ). However, as expected, it failed to activate the cis-bound, RARregulated HoxA1 gene ( Figure 1G ).
Administration of ICI 182780 to knockdown ERa caused a loss of RAR binding at the ERa-regulated enhancers ( Figures 2D, S3C , and S3D), but did not alter the binding of RARa or RARg at activated enhancers harboring cis RAR binding sites (data not shown). Knockdown of RAR did not cause downregulation of ERa RNA or protein levels ( Figures S2B and S2C ) and did not affect the ERa binding pattern on ERa active enhancers ( Figure 1H) .
Collectively, our data indicate that ERa selectively recruits RARa and RARg in trans on the functional enhancers regulating the most robustly activated target coding genes and that this strong activation depends on the ERa-mediated trans-binding of RARs.
ERa Recruits a Mega DNA-Binding Transcription Factor Complex In Situ at Functional ERa Enhancers These findings prompted us to examine the behavior of additional DNA-binding TFs associated with ERa, based on previously reported mass spectrometry analysis of proteins that coimmunoprecipitated with ERa (Mohammed et al., 2013) as well as our own confirmatory data. From these ERa complex data, we noted a number of DNA-binding transcription factors associated with ERa, including RARg, GATA3, AP2g, STAT1, and, intriguingly, FoxA1. To complement these observations, we also examined the proteins associated with RAR following pull down from MCF7 cells stably expressing, at physiological levels, biotin-tagged RARa ( Figures S1D and S3A ). In addition to RARa, RXRs, and many well-known cofactors for nuclear receptors, GATA3 was also detected along with other DNA-binding proteins including AP2g, STAT1, c-Fos, and FoxA1 (Figure 2A) . We then performed gel filtration analysis on nuclear extracts prepared from MCF7 cells in the absence of DNase treatment and analyzed all fractions for ERa, RARa/g, GATA3, and the other DNA-binding transcription factors identified in the mass spectrometry analysis. This analysis revealed co-elution of ERa, RARa, RARg, GATA3, AP2g, FoxA1, STAT1, c-Fos, and other proteins in an estimated 1-2 MDa complex(es) ( Figure 2B ). These components were all present in ERa-immunoprecipitates from nuclear extracts and their association was enhanced upon E 2 treatment ( Figure S3B ). Importantly, knockdown of nuclear ERa by administration of ICI 182780 caused a virtual loss of the entire complex associated with ERa by gel filtration analysis (Figures 2C and S3C) and recruitment of each factor to ERabound functional enhancers ( Figures 2D and S3D) . Thus, the material co-migrating in the gel filtration represented proteins interacting as a complex with ERa rather than artifacts. This complex remained intact in the presence of 250 mM NaCl, but was lost under 600 mM NaCl high-salt conditions (data not shown).
To further investigate the hypothesis that the ERa-dependent trans-recruitment/assembly of other DNA-binding transcription factors occurs only in situ at ERa active enhancers, we first confirmed that the interactions between ERa and the TFs were dependent on DNA ( Figure S3E ). Using a non-DNA-binding ERa pBox mutant, which is incapable of binding the estrogen response element (ERE) motif (Stender et al., 2010) , we could show that this mutation abolished the interactions of ERa and these associated TFs ( Figure 2E ). As a control, a comparable RARa pBox mutant did not affect its interaction with ERa and these TFs ( Figure 2F ). These data suggest that RARa and other TFs are recruited by ERE-bound ERa to its activated enhancers; thus, the entire complex is assembled in situ on ERa-bound enhancers.
To further confirm that these factors were, indeed, co-recruited to the same transcription units, rather than the consequence of differential recruitment behavior in different cell populations, we performed serial pairwise two-step ChIP analyses to assess the co-recruitment of RARa with ERa, GATA3, FoxA1, AP2g, and STAT1 on the same ERa-bound enhancers. Using a BLRPtagged RARa stable cell line, two-step ChIP was performed with biotin-streptavidin pull-down of RARa in the first round followed by immunoprecipitation with antibodies for RARa (as positive control), ERa, GATA3, FoxA1, AP2g, and STAT1. In each case, we found that these proteins were present on the interrogated active enhancers, including the GREB1 enhancer ( Figure 2G ). In contrast, as a control, this was not the case for the RAR cis-bound enhancer regulating the HoxA1 transcription unit ( Figure 2H ). Thus, the MegaTrans complex was co-recruited to ERa-bound active enhancers but not to functional enhancers that directly bind RARa in cis. RARa and the other TFs also were not present at ERa-bound, non-active enhancers (Figure 2I) . Double-ChIP experiments performed with a BLRP-tagged GATA3 stable line similarly demonstrated the co-binding of GATA3 with ERa and all of the other TFs at ERa active enhancers but not at either the HoxA1 enhancer or ERa non-active enhancers ( Figure S3F ). Together, these data indicate that a feature (legend continued on next page) of the active, regulatory ERa-bound enhancers, in addition to their increased levels of eRNA transcription, is the selective recruitment of this MegaTrans complex.
trans-Bound GATA3 Also Regulates Functional ERa Enhancers
To explore the possible functional consequences of the additional ERa-interacting transcription factors, we next explored the potential recruitment and function of GATA3 on ERa active and non-active enhancers. ChIP-seq experiments revealed, as in the case of RARa and RARg, that GATA3 was recruited in an E 2 -dependent fashion to active enhancers ( Figure 3A) but not non-active enhancers ( Figure 3B ). Because we found the presence of GATA3 on functional ERa-bound enhancers that did not harbor apparent GATA3 cis-binding elements by motif analysis, we again assessed the possibility that GATA3 was recruited in trans to these ERa-bound active enhancers. Knockdown of ERa by administration of ICI 182780 inhibited GATA3 recruitment to ERa active enhancers ( Figures 2D and S3D) . Because direct or indirect ERa and GATA3 interactions were suggested by immunoprecipitation experiments ( Figure S3B ), we investigated the consequences of disrupting the ability of GATA3 to bind to cognate DNA sites by two different mutations of the second zinc finger that is required for cis-binding of GATA3 (Nesbit et al., 2004) (Figure S4A ). We generated inducible BLRP-tagged stable lines expressing wild-type and the two DNA-binding mutants at physiological levels ( Figure S4B ), and biotin ChIP-seq revealed they were equivalently recruited, apparently in trans, to these ERa-bound active enhancers ( Figures 3B and S4C) . By comparing the ChIP-seq data for wild-type and DNA-binding mutants, we found that among 18,000 wild-type GATA3 binding peaks 5,000 were retained in the two GATA3 mutants, and these trans-binding sites featured ERE as the top motif by Homer analysis ( Figure S4D ). For the 13,000 cis-binding peaks, GATA motifs were enriched and a heatmap of the non-ERa enhancers containing a GATA motif was used to confirm a total loss of binding of the two non-DNA-binding GATA3 mutants ( Figures 3C and  S4D) .
Using qPCRs or GRO-seq analysis, we explored the consequences of specific siRNA-mediated knockdown of GATA3 on E 2 -dependent induction of eRNAs. We found a dramatic inhibition of the eRNA activation events on active enhancers ( Figures  3D, 3E , and S4E) but no effect on ERa-bound non-active enhancers or non-ERa-bound enhancers ( Figure 3E ). The same inhibition effects were also found for gene body expression of the targets of these 1,333 ERa active enhancers ( Figures 3D, 3E , and S4E). Knockdown of GATA3 did not affect ERa gene expression at either the RNA or protein level (Figures S4F and S4G) or ERa binding at active enhancers ( Figure 3F ). Thus, GATA3 and RARs, as components of a complex of DNA-binding TFs associated in trans with ERa on active enhancers, are required for E 2 -dependent enhancer activation.
ERa Active Enhancers Are Regulated by the MegaTrans Complex
We next investigated whether other DNA-binding transcription factors in the MegaTrans complex co-migrating with ERa were also recruited to E 2 -actived enhancers even in the absence of their cognate DNA-binding elements. We reviewed our own and published ChIP-seq data from MCF7 cells for other DNAbinding TFs present in the MegaTrans complex (Joseph et al., 2010; Theodorou et al., 2013) . E 2 -regulated active enhancers were found to harbor AP2g, FoxA1, c-Jun, and c-Fos, along with RARa/g and GATA3 ( Figures 4A and 4B ), but these TFs were not present on non-active enhancers ( Figures 4A and S5A ). Similar to RARa/g and GATA3, the recruitment of the other TFs was also increased by E 2 and abolished by knockdown of nuclear ERa using ICI 182780 ( Figures 4C, 2D , and S3D).
In order to investigate whether, in fact, all DNA-binding transcription factors present in the MegaTrans complex were recruited in trans to ERa functional enhancers, a series of DNA-binding domain mutations were generated for AP2g, c-Fos, c-Jun, and STAT1. ChIP-qPCR data on the GREB1 and TFF1 enhancers showed that the binding of the non-DNA-binding mutants at these two ERa active enhancers was comparable to that of the wildtype proteins ( Figure 4D ), which confirms the trans-recruitment of these TFs by ERa.
Based on the roles of RARs and GATA3 on ERa active enhancers, we evaluated the functional effects of other recruited transcription factors. Beginning with AP2g, we found that, in addition to its recruitment in response to E 2 on ERa regulatory enhancers ( Figure 4C ), knockdown of AP2g caused a dramatic inhibition of eRNA and target coding gene expression, as assayed by both qPCR and GRO-seq ( Figures 4E, S5B , and S5C). Similarly, as STAT1 was also recruited to ERa-bound enhancers ( Figures 2D and S3D) , we evaluated its effect on two well-described ERa bound/regulated enhancers. Again, we found a functional contribution to the outcome of E 2 -induced activation of enhancer transcription and target coding gene expression ( Figure 4F ). The same regulatory effects were also demonstrated upon knockdown of two AP1 components, cJun and c-Fos ( Figures S5D and S5E) , that were present in the MegaTrans complex ( Figures 4A and 4B) .
To begin to assess the interdependency of the components of the MegaTrans complex on recruitment to ERa-bound functional enhancers, we tested the consequences of knockdown of RARa/g, GATA3, and AP2g on GREB1 and TFF1 enhancer occupancy. We found a marked inhibition of recruitment of other MegaTrans components upon knockdown of RARa/g and GATA3 ( Figures 4G and 4H) but not by knockdown of AP2g (B) Heatmaps of ChIP-seq data for wild-type and two DNA-binding mutants of GATA3 (+E 2 ) show the binding of GATA3 to these ERa active enhancers is not dependent on its DNA-binding ability. There is no binding of either wild-type or mutant GATA3 to ERa non-active enhancers. (C) Heatmap of ChIP-seq data for wild-type and two DNA-binding mutants of GATA3 (+E 2 ) shows the binding of GATA3 to these non-ERa enhancers that contain the GATA motif requires its DNA-binding ability.
(legend continued on next page) ( Figure 4I ), consistent with interdependency of at least some components of the complex for recruitment of other components. RARa/g and GATA3 may serve as key functional components, along with ERa, in recruitment/assembly of the MegaTrans complex on functional ERa-bound enhancers.
FoxA1 Is Required for ERa Recruitment and MegaTrans Complex Stabilization on ERa Active Enhancers
These experiments raised a question about potential differences in DNA sequence features between ERa active enhancers that bound the MegaTrans complex and ERa non-active enhancers that did not. Comparison of the EREs between these two groups revealed that its frequency and the primary consensus sequences were essentially identical ( Figure 5A ). In contrast, and in accord with the well-known importance of FoxA1 as a pioneer factor for ERa binding (Hurtado et al., 2011) , we noted that the functional, MegaTrans-bound 1,333 ERa active enhancers generally harbor a FoxA1 binding motif within 200 bp of the ERE sites, while the FoxA1 motif was virtually absent on the nonfunctional, non-MegaTrans-bound ERa enhancers (Figure 5B) . Indeed, the affinity for ERa is >90% lower on the nonfunctional than functional ERa-bound enhancers ( Figure 5C ). Consistent with FoxA1 functioning as a key determinant of ERa binding (Hurtado et al., 2011) , our data showed greatly reduced binding of ERa at the 1,333 ERa-bound active enhancers upon FoxA1 knockdown ( Figure 5D) .
Because FoxA1 appears to be a component of the MegaTrans complex based on gel filtration and coimmunoprecipitation (co-IP) data (Figures 2B and S3B) and also exhibits E 2 -induced binding at the 1,333 ERa active enhancers ( Figure 5E ), we speculate that FoxA1 potentially plays dual roles in the binding of ERa to functional enhancers and in ERa-dependent recruitment of the MegaTrans complex. Indeed, knockdown of FoxA1 caused a dramatic impairment of ERa binding on the functional ERa enhancers ( Figure 5D ), which was accompanied by a loss of recruitment of the MegaTrans complex on this functional enhancer cohort ( Figure 5F ) and inhibition of both eRNA and gene body activation ( Figure 5G ). Thus, FoxA1 is distinct from the other DNA-binding TFs in the MegaTrans complex that apparently do not affect ERa binding upon knockdown ( Figures  1H and 3F) .
Roles of MegaTrans Complex in Coactivator Recruitment and in Super-Enhancer Function
A basic aspect of the mechanism by which MegaTrans components function is their requirement for effective activation of E 2 -induced eRNAs on the functional enhancers. Accordingly, we assessed the recruitment of the coactivator p300 by qPCR and ChIP-seq upon knockdown of RARa/g or GATA3. All of these knockdowns inhibited the E 2 -induced accumulation of p300 on activated enhancers ( Figures 6A-6C , and S6A), consistent with a previous report of a role for RARa in p300 recruitment (Ross-Innes et al., 2010). Based on the importance of Mediator complex for enhancer function, putatively due to its roles in enhancer:promoter looping events (Kagey et al., 2010) , we also evaluated the effects of RARa/g and GATA3 knockdown on E 2 -dependent recruitment of Med1 to functional enhancers by qPCR, finding a dramatic inhibition following these knockdowns ( Figures 6A  and 6B ). This result was confirmed genome-wide by ChIP-seq ( Figures 6D and S6B) .
Based on the criteria developed in the initial description of super-enhancers Whyte et al., 2013) , we assessed the number of super-enhancers in MCF7 cells by Med1 ChIP-seq under both -E 2 and +E 2 conditions. While there are only 122 super-enhancers under the -E 2 condition, E 2 treatment increases the total to 320 such enhancers ( Figure 6E ), of which 212 contained at least one ERa-bound functional enhancer, including one at the c-Myc gene locus ( Figure S6C ). Thus, only 300 of the 1,333 ERa-bound functional enhancers characterized by MegaTrans complex fulfill the current definition of being located in super-enhancers. The efficacy of this subset of 300 ERa-bound active enhancers was only slightly better than the other 1,033 ERa-bound active enhancers with respect to eRNA induction ( Figure 6F) . Thus, the functional strength of the ERa-bound enhancers, irrespective of their presence in a super-enhancer, is predicted by the presence of the MegaTrans complex.
Actually, for the 212 super-enhancers that contain ERa active enhancers, their Med1 levels were also dependent on the E 2 signal ( Figure S6C ). Interestingly, we observed greatly reduced levels of Med1 at these 212 super-enhancers following knockdown of RARs ( Figure 6G ), suggesting that MegaTrans enhancers are important constituents in the function of these clustered super-enhancers.
DNA-Binding TFs of the MegaTrans Complex Might Recruit Specific Functionally Required Components for Enhancer Activation
Based on the presence of specific non-transcription factor components in the mass spectrometry analysis of RARa-associated proteins (Figure 2A) , we evaluated the functional significance of these additional proteins. We elected to focus on DNA-dependent protein kinase (DNA-PK), comprising the catalytic subunit DNA-PKcs, Ku70, and Ku80, because all three DNA-PK subunits were present in the RARa pull down as revealed by mass spectrometry. We confirmed these associations by co-IP and western blot analysis ( Figure 7A ). DNA-PKcs has previously been reported as a component of the ERa complex that directly phosphorylates S118 of ERa (Foulds et al., 2013) , and we confirmed that knockdown of DNA-PKcs partially impacted phosphorylation of ERa S118 without affecting ERa binding at ERa active enhancers ( Figure 7B ). Using a specific antibody against DNAPKcs for ChIP analysis, we first evaluated the temporal kinetics of its potential recruitment on the GREB1 and TFF1 enhancers, (legend continued on next page) finding recruitment at 10 min following E 2 treatment of MCF7 cells ( Figure 7C ). In addition, a specific antibody against phosphorylated ERa S118 revealed strong enrichment that peaked at 20 min, slightly after the recruitment of ERa and DNA-PKcs ( Figure 7C ). Based on these observations, we conducted ChIPseq analysis of DNA-PKcs in MCF7 cells after 10 min of E 2 treatment, which revealed 12,629 peaks that mostly located in intergenic regions ( Figure S7A ). Of the detected peaks, 971 were on the ERa-bound, MegaTrans-containing active enhancers but few were present on non-active enhancers ( Figures 7D and  S7B) . A second antibody for DNA-PKcs yielded similar ChIPseq results, confirming the specificity of the signal (data not shown).
In order to determine whether trans-bound RAR is required for the recruitment of DNA-PKcs at ERa active enhancers, we performed ChIPs for both DNA-PKcs and pERaS118 after knockdown of RARa/g. We found that RARa/g knockdown substantially reduced the levels of both DNA-PKcs and pERaS118 at ERa active enhancers ( Figures 7E-7G , S7C, and S7D), suggesting that trans-bound RARs may be required for the functionally relevant recruitment of DNA-PKcs at these ERa enhancers.
Knockdown of DNA-PKcs significantly inhibited E 2 -induced activation of ERa-bound functional enhancers and their target coding gene expression but did not affect RA-induced HoxA1 activation ( Figure 7H) . Consistently, the treatment of MCF7 cells with the DNA-PK kinase inhibitor NU7441 also inhibited ERa-dependent target activation ( Figure S7E) . Thus, at least one role of RARs that are recruited to ERa-bound functional enhancers may be to facilitate the concomitant recruitment of a specific protein kinase. It is possible that, analogous to this role of RARs in recruitment of DNA-PK, other DNA-binding TFs components in the MegaTrans complex also contribute to the recruitment of additional enzymatic factors that are required for functional enhancer activation.
DISCUSSION The MegaTrans Complex Is a Signature of ERa Functional Enhancers
Here, we suggest that, in addition to the critical recruitment of an ever-increasing number of well-characterized coactivator complexes, many with specific enzymatic functions, activation of the most robust subset of ERa enhancers by E 2 is dependent upon, and can be predicted by, their ability to recruit a complex of established DNA-binding transcription factors, referred to as the MegaTrans complex ( Figure 7I) . This complex appears to be recruited/assembled in trans on ERa-bound functional enhancers and requires the presence of ERa. In addition to the requirement for ERa, certain other components of the complex appear to be necessary for its assembly on functional enhancers; for example, knockdown of RARa/g and GATA3 abolishes recruitment of other components of the complex and inhibits enhancer/target coding gene activation. Although the precise biochemical interactions that underlie the formation of the MegaTrans complex remain incompletely defined, our data on the effects of DNase I treatment and DNA-binding domain mutation suggest that the MegaTrans complex assembles in situ at ERabound, ERE-containing enhancers, which also typically harbor nearby FoxA1 cis-binding sites.
While the idea that DNA-binding transcription factors can be recruited in trans to either activate or repress specific target coding genes is well established (Langlais et al., 2012; Pascual et al., 2005; Reichardt et al., 1998) , this study provides an initial description of a ligand-dependent recruitment in trans of a complex of DNA-binding transcription factors that proves important for ERa function. Using the published criteria for defining super-enhancers Whyte et al., 2013) , only 22% of the functional MegaTrans enhancers can be classified as components of super-enhancers, and we note that there is only a very slight distinction in the levels of eRNA induction in response to E 2 on the functional MegaTrans enhancers associated with super-enhancers compared to those not associated with the super-enhancers. Thus, recruitment of the MegaTrans complex serves as a mark that distinguishes the most active enhancers of the estrogen-regulated transcriptional program.
These observations raise several corollary questions. First, does this MegaTrans complex serve on all active or activated enhancers, irrespective of the DNA-binding transcription factors bound in cis to those enhancers? It appears that the RARE-containing functional enhancers, which recruit RARa/g in cis, do not recruit this complex or ERa ( Figure S1G ). Therefore, we speculate that there may be a number of distinct MegaTrans complexes that are recruited only by certain regulatory DNA-binding factors, and these complexes, analogous to events for ERa-regulated enhancers, serve to mark and initiate other specific enhancer activation events. Second, how is the MegaTrans complex selectively recruited only to the functional ERa-bound enhancers? Based on our initial data, we suggest that the answer likely involves the apparent dual roles of the ''pioneer factor'' FoxA1, which is selectively recruited to the functional, MegaTrans-dependent enhancers at <200 bp from the ERE but is also required for the binding of ERa to these enhancers. In addition to its established pioneering role, FoxA1 may also make an important contribution to the recruitment/stabilization of the MegaTrans complex. We are tempted to speculate that, in addition to promoting cooperative binding of ERa to enhancers, FoxA1 may cause a conformational alteration in the ERa receptor, either directly or via altered enhancer DNA architecture, that facilitates the recruitment of the MegaTrans complex; however, it is formally possible that the increased affinity of ERa for the enhancer alone determines binding of the MegaTrans complex. These questions and other undefined aspects of the MegaTrans complex represent fascinating issues for future investigation. 
The MegaTrans Complex as a Platform for Regulatory Enzymes
In light of the already large number of important coactivator complexes, why would these additional DNA-binding transcription factors, most of which are recruited to the active enhancers by the ERE-bound ERa, be required? First, we have found that they play important ''early'' roles in enhancer function as they are important for eRNA induction and the ligand-dependent increase of p300 and Med1 occupancy on the enhancers. Thus, components of the MegaTrans complex are required to license the recruitment of well-known, important coactivators, as exemplified by p300 and Mediator subunits. In this regard, the DNA-binding transcription factors summoned to bind in trans through ERa are subserving functions that are quite analogous to those of the recognized coactivator complexes, many of which feature associated/intrinsic enzymatic activities. Similarly, we note that RARs are capable of interacting with many known or potential coactivators, and we have focused on one such potential regulator. The enzyme DNA-PKcs binds to RARs and is recruited with rapid temporal kinetics to ERa-bound functional enhancers. Additionally, knockdown of DNA-PKcs partially phenocopies the functional consequences of RARa/g knockdown in MCF7 cells. Therefore, we are tempted to speculate that components of the MegaTrans complex individually recruit various enzymes/factors that collectively are mechanistically important in initial activation of the functional enhancer program. DNA-PK is a kinase with multiple targets, including ERa on Ser118 (Foulds et al., 2013) , which we find occurs on the active ERa-bound enhancers, dependent on the presence of RARs on these functional enhancers. It is particularly intriguing that DNA-PKcs is associated with the Ku80 complex, classically considered to be involved in DNA damage repair (Hartley et al., 1995; Jin and Weaver, 1997) , which may in fact be pertinent to its functions in transcriptional control events. The rapid appearance of DNA-PKcs on the ligand-regulated enhancers is analogous to other examples of recruited protein kinases in gene regulation events (Perissi et al., 2008; Tee et al., 2014) . (F) A boxplot analysis based on GRO-seq data (+E 2 ) of eRNA expression levels for two groups of ERa active enhancers: the 300 ERa active enhancers located in super-enhancers (median: 5.14) and 1,033 ERa active enhancers that are not located in super-enhancers (median: 3.59). (G) Tag density plot showing knockdown of trans-bound RARs, which affects the function of ERa active enhancers, reduces the E 2 -enhanced Med1 signal at 212 super-enhancers that contain ERa active enhancers. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01. See also Figure S6 .
Thus, investigation of the ERa-regulated enhancers has revealed that an additional and critical component of the most active enhancers is the ERa-dependent recruitment of the MegaTrans complex, which promotes combinatorial recruitment of additional coactivators/enzymes that increase enhancer activation and target coding gene transcription. Analogous to the hypothesis that super-enhancers regulate critical developmental or disease-associated coding gene transcriptional programs, MegaTrans complex recruitment appears to serve as a mechanism of marking/empowering enhancers to control key aspects of the regulatory transcriptional programs in a specific cell type. The super-enhancer model defines the combinatorial effects of multiple, clustered enhancers spanning >8-10 kb, while the MegaTrans enhancer model explains the differential functional activity of single enhancers.
MegaTrans Enhancers as a Commonly Utilized Strategy?
The uncovering of another layer of machinery involved in the effective activation of ERa-regulated enhancers raises the possibility that distinct MegaTrans enhancers exist for other classes of DNA-binding TFs that are responsible for activation of unique transcriptional programs. We note that ChIP-seq analyses for many established DNA-binding TFs have revealed their binding on enhancers that do not harbor any known cognate binding sequences. This raises the possibility that these TFs might exert roles, in trans, on other transcription programs analogous to the effects of the MegaTrans complex on the ERa-regulated functional enhancers. The ''hotspot'' or ''clustering'' phenomenon of DNA-binding TFs has recently been reported in several different organisms (Junion et al., 2012; Rada-Iglesias et al., 2012; Siersbaek et al., 2014a; 2014b; Wilson et al., 2010; Yan et al., 2013) . However, the underlying molecular mechanism(s) and functional significance are not well understood. Our results provide a functional model to explain at least many cases of the clustering phenomena. Specifically, our data suggest that the DNA-dependent binding of ERa and FoxA1 at ERa functional enhancers establishes a platform for recruiting a MegaTrans complex of other DNA-binding TFs by protein-protein interactions (in trans). MegaTrans complex-bound enhancers function as more robust enhancers by recruiting certain unique factors and enzymes, such as DNA-PK. Thus, our study provides insights into understanding the phenomenon of TF clustering. Our data also simultaneously help to explain why ChIP-seq analyses reveal 50% of the regions occupied by many of the DNA-binding TFs assayed in the ENCODE project do not harbor cognate DNAbinding motifs.
EXPERIMENTAL PROCEDURES
A detailed description of all methods and any associated references is provided in the Extended Experimental Procedures (including Tables S1, S2 , and S3), which can be found in the supplemental data section.
Cell Culture and BLRP-Tagged Stable Cell Lines MCF7 cells, initially obtained from ATCC, were maintained in culture and treated as described . To study binding patterns for wild-type and non-DNA-binding mutants of RARa/g, GATA3, ERa, and other TFs, we first established a parental MCF7 stable cell line that expressed BirA enzyme and Tet-Repressor. We then used this parental cell line to make doxycyclineinducible stable cell lines expressing BLRP-tagged proteins at close to endogenous levels. BLRP-tagged proteins were biotinylated in vivo by BirA enzyme, allowing for pull downs to be performed with NanoLink streptavidin magnetic beads (Solulink) under very stringent washing conditions.
Chromatin Immunoprecipitation and Global Run-on Sequencing
ChIP-qPCRs, ChIP-seqs, and GRO-seqs were performed as previously reported . Immunoprecipitated DNA was recovered by purification on QIAquick spin columns (QIAGEN) after decrosslinking and then analyzed by qPCR using primers listed in Table S1 . The qPCR-validated DNA samples were used to make libraries for deep sequencing. The details of ChIP-seq and GROseq data analysis are included in the Extended Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus databank accession number for all deep sequencing data reported in this paper is GSE60272, which includes ChIPseq data sets (GSE60270) and GRO-seq data sets (GSE60271). 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental
